Goldline Pharmaceutical IPO Financials
The Goldline Pharmaceutical IPO provide an overview of the company's performance over the previous financial periods. Investors can evaluate key financial metrics such as assets, revenue, profit after tax (PAT), net worth, reserves & surplus, and total borrowings to assess the company's financial strength, profitability, and long-term growth potential before investing in the IPO.
As of 31 Dec 2025, Goldline Pharmaceutical Limited reported assets of ₹27.4 crore, revenue of ₹21.41 crore, and a profit after tax (PAT) of ₹2.22 crore. The company had a net worth of ₹12.36 crore and reserves & surplus of ₹3.65 crore, and total borrowings are 9.47 crore.
Revenue increased by 31.06% in 31 Mar 2025 and decreased by 16.00% in 31 Mar 2024 and decreased by 15.78% in 31 Mar 2023, while Profit After Tax (PAT) grew by 27.48% in 31 Mar 2025 and declined by 36.04% in 31 Mar 2024 and declined by 85.64% in 31 Mar 2023, respectively.
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
Goldline Pharmaceutical Limited Financials (₹ in Crores)
| Particular | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 27.4 | 26.28 | 22.93 | 19.39 |
| Revenue | 21.41 | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.22 | 2.83 | 1.81 | 0.26 |
| Net Worth | 12.36 | 10.35 | 7.86 | 5.89 |
| Reserve & Surplus | 3.65 | 1.65 | 3.76 | 2.08 |
| Total Borrowings | 9.47 | 11.03 | 11.13 | 10.83 |
EPS Pre
4.11%
EPS Post
2.95%
P/E Pre
10.47
P/E (Post Issue)
14.56x
Company Financial Information
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Revenue of Goldline Pharmaceutical Limited?
Goldline Pharmaceutical Limited reported revenue of ₹21.41 crore as of 31 Dec 2025. Revenue figures from the Goldline Pharmaceutical IPO provide insights into sales growth, market demand, and business scalability.
What is the Profit After Tax (PAT) of Goldline Pharmaceutical Limited?
Goldline Pharmaceutical Limited reported a Profit After Tax (PAT) of ₹2.22 crore as of 31 Dec 2025. PAT represents the company's net profit after deducting all operating expenses, interest, taxes, and other applicable charges, making it a key indicator of overall profitability.
What is the PE Ratio of Goldline Pharmaceutical Limited?
Goldline Pharmaceutical Limited has a Price-to-Earnings (P/E) ratio of 10.47x based on the IPO issue price. The P/E ratio compares the company's share price with its earnings per share (EPS) and is a commonly used valuation metric to assess whether a stock is fairly valued relative to its earnings and industry peers.